These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1601534)

  • 1. Lack of pharmacokinetic interaction as an equivalence problem.
    Steinijans VW; Hartmann M; Huber R; Radtke HW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S63-8. PubMed ID: 1601534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of pharmacokinetic interaction as an equivalence problem.
    Steinijans VW; Hartmann M; Huber R; Radtke HW
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S25-30. PubMed ID: 8793601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of pharmacokinetic interaction as an equivalence problem.
    Steinijans VW; Hartmann M; Huber R; Radtke HW
    Int J Clin Pharmacol Ther Toxicol; 1991 Aug; 29(8):323-8. PubMed ID: 1835963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):105-10. PubMed ID: 2318545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence studies: single vs multiple dose.
    Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies.
    Schall R; Hundt HK; Luus HG
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):633-7. PubMed ID: 7881699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reference tables for the intrasubject coefficient of variation in bioequivalence studies.
    Steinijans VW; Sauter R; Hauschke D; Diletti E; Schall R; Luus HG; Elze M; Blume H; Hoffmann C; Franke G
    Int J Clin Pharmacol Ther; 1995 Aug; 33(8):427-30. PubMed ID: 8556220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of influence of glycine on the single dose pharmacokinetics of acetylsalicylic acid in man.
    Schurer M; Bias-Imhoff U; Schulz HU; Schwantes U; Riechers AM
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):282-7. PubMed ID: 8832303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A confirmatory strategy for therapeutic equivalence trials.
    Kieser M
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):388-90. PubMed ID: 7582393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.
    Mignini F; Tomassoni D; Streccioni V; Traini E; Amenta F
    Clin Exp Hypertens; 2008 Feb; 30(2):95-108. PubMed ID: 18293165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bio-equivalence and generic drugs. Studies of bio-equivalence. II. Special situations. Reflections on problems which may arise with drugs habitually used in neurology].
    Zapater P; Horga JF
    Rev Neurol; 2000 Jan 16-31; 30(2):146-54. PubMed ID: 10730322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimum allocation of treatments for Welch's test in equivalence assessment.
    Dette H; Munk A
    Biometrics; 1997 Sep; 53(3):1143-50. PubMed ID: 9333344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.